[Autoinflammatory syndromes in dermatology].

Area of Science:

• Immunology
• Genetics
• Rheumatology

Background:

• Hereditary periodic fever syndromes, or autoinflammatory syndromes, are characterized by recurrent fevers and associated symptoms like rashes or joint pain.
• Genetic mutations are identified in most of these disorders, leading to excessive interleukin-1beta (IL-1beta) production.
• These conditions manifest with systemic inflammation, impacting various organs and tissues.

Purpose of the Study:

• To summarize the key features and genetic underpinnings of hereditary periodic fever syndromes.
• To highlight the role of interleukin-1beta (IL-1beta) in the pathogenesis of these diseases.
• To review current therapeutic strategies, including IL-1beta inhibition and other targeted treatments.

Main Methods:

• Literature review of hereditary periodic fever syndromes.
• Analysis of genetic mutations associated with autoinflammatory disorders.
• Evaluation of treatment outcomes for IL-1beta inhibitors and other therapies.

Main Results:

• Most hereditary periodic fever syndromes are linked to specific gene mutations causing uncontrolled IL-1beta production.
• IL-1beta inhibition via receptor antagonists or monoclonal antibodies is a successful treatment for many of these syndromes.
• Specific treatments like TNF-antagonists for TRAPS and PGA, and colchicine for FMF, are also highlighted.

Conclusions:

• Hereditary periodic fever syndromes are genetically driven inflammatory conditions.
• Targeting IL-1beta is a cornerstone therapy for a majority of these autoinflammatory diseases.
• Personalized treatment approaches considering specific syndromes and genetic profiles are crucial for effective management.